Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Aim of the study is to evaluate the safety and find the maximal tolerated dose of VB-111 in Patients with Advanced Metastatic Cancer
Nine Cohorts of dose escalating VB-111 were completed with a total of 56 subjects enrolled.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| VB-111 | Drug | A single intravenously infusion of diluted VB-111 should be administered 1 ml/minute |
|
| Measure | Description | Time Frame |
|---|---|---|
| Response and progression will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) | 2 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pierre Triozzi, Dr. | The Cleveland Clinic | Principal Investigator |
| Andrew Brenner, MD | UTHSC- CTRC and Institute for Drug Development | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dana Farber/Brigham and Women's Cancer Center | Boston | Massachusetts | 02215 | United States | ||
| Cleveland Clinic |
| Type | Date | Date Unknown |
|---|---|---|
| Release | May 31, 2023 | |
| Reset | Feb 7, 2024 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Cleveland |
| Ohio |
| 44129 |
| United States |
| UTHSC- CTRC and Institute for Drug Development | San Antonio | Texas | 78229 | United States |
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| May 31, 2023 | Feb 7, 2024 |